Abstract
Introduction:
To analyze the current state, hotspots, and cutting-edge trends of genomics research on the outbreak of Corona Virus Disease 2019 (COVID-19) from 2019 to the present (March 2022).
Methods:
Statistical and visual analysis of COVID-19 genomics results published in the 2019-2022 Web of Science Core Collection Database (WOSCC) was performed using CiteSpace software, including data on countries, institutions, authors, journals, co-citations, keywords, etc.
Results:
A total of 9133 English literature were included. The number of publications has significantly increased in 2021, and it is expected that this upward trend will last into the future. The research hotspots of COVID-19 revolve around quarantine, biological management, angiotensin-converting enzyme-2, RNA-dependent RNA polymerase, etc. Research frontiers and trends focus on molecular docking, messenger RNA, functional receptor, etc.
Conclusion:
The last two years have seen a significant increase in research interest in the field of novel coronavirus pneumonia genomics.
Introduction
The Corona Virus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in millions of confirmed cases and fatalities worldwide (; ) and has led to a global crisis that has elevated to the status of a public health emergency global concern (). The most common clinical symptoms of COVID-19 disease are respiratory symptoms, such as dry cough, fever, and shortness of breath. Some patients also experience other symptoms, including abdominal pain and diarrhea, neurological damage, headache, myalgia, and fatigue (). A recent study of 401 cases (aged 51-81 years) who tested positive for SARS-CoV-2 infection found greater reductions in overall brain volume and greater cognitive deterioration between time points (). Antiviral drugs currently commonly used to treat ribavirin (nucleoside analogs), lopinavir/ritonavir (protease inhibitors), remdesivir and favipiravir may be potentially effective in the treatment of COVID-19, including IL-6 monoclonal antibodies, tyrosine-protein kinase 1/2 inhibitors, cell therapy drugs, etc (; ; ; ).
The genomic study of the new coronary pneumonia epidemic has gained attention due to potential mutations in the internal gene sequences of the SARS-CoV-2 since the Human Genome Project’s completion and the advent of bioinformatics technology. The knowledge based on the impact of SARS-CoV-2 spike mutations on antigenicity and other aspects of viral biology is rapidly expanding, and the integration of gene sequences has the potential to facilitate potentially interesting variants (). Global genomics-based monitoring of new variants of COVID-19 will continue to be a key component in collecting and making available online information on all SARS CoV-2 lineages, enabling rapid assessment of their influence on transmission, virulence, and vaccine escape (). Understanding the structural and functional characteristics of SARS CoV-2 protein is crucial to promote the development of anti-CoV drugs and vaccines that could prevent and control the current SARS CoV-2 pandemic (). Sali Abubaker Bagabir et al. used artificial intelligence technology (AI) to open the door to the genome sequence of the COVID-19 virus and variants of concern (VOC), and found that spike protein was the gene with the most genes among genes for vaccine discovery ().
Bibliometric analysis is a popular method for analyzing large amounts of scientific data. It discovers knowledge associations between documents by filtering and processing large amounts of information and is used in various applications such as biomedicine, economic management, information science, renewable energy, and the environment (; ; ). The use of bibliometric theories and methods to scientifically analyze specific journals is one of the important topics of bibliometrics (), which provides a comprehensive perspective for conducting research and is of great significance for scholars to grasp the hot spots in this field promptly (). CiteSpace is designed by Professor Chen for quantitative information acquisition and visualization in specific fields and is considered to be one of the most influential software in the field of bibliometrics and information visualization (; ).
This study used CiteSpace software (version 5.6. R3) to visualize and analyze the pertinent literature on novel coronavirus pneumonia genomics published in the WOSCC Database from 2019 to 2022, and to summarize the research status and hot frontiers of COVID-19 in the field of genomics, which provides reference and ideas for the development of COVID-19 genomics targeted laboratory characterization studies and the updating of antigen variant vaccines.
Materials and methods
Data sources
Search strategy: TI= (“COVID 19” OR “atherosclerotic” OR “Severe Acute Respiratory Syndrome Coronavirus 2 Infection” OR “SARS-CoV-2” OR “Coronavirus Disease 19” OR “Coronavirus Disease 2019” OR “2019 Novel Coronavirus*”) AND TS= (“genomics” OR “genome*” OR “DNA” OR “RNA”). Time span: 1999~2022; Index: SCI-EXPAND-ED. The types of included documents are “Article” and “Review”, and the language is “English”.
Method
CiteSpace software () was used to visualize and analyze COVID-19 genomics-related literature in the WOSCC. The SCI-EXPANDED WOSCC Database was selected because it efficiently represented the search results. Therefore, it is recommended to use it to search for journals and references (). The specific method is to use CiteSpace software to integrate and deduplicate, finally obtain a total of 9133 documents, analyze the data of countries, institutions, authors, journals, co-cited references, keywords, and other data and draw a visual map. The software time parameters are set from 2019 to 2022 with a time slice of 1 year. The appropriate thresholds were selected according to different nodes, and the map clipping methods were set to Pathfinder, Pruning sliced networks, and Pruning the merged network.
Results
Literature distribution
A total of 9133 articles were retrieved and exported in plain text format from 2019 to 2022. In 2019, two papers will be published, which is the outbreak period of COVID-19; 2,431 papers will be published in 2020, which is a growth period; 5,852 papers will be published in 2021, which is a period of rapid growth and research hotspot; 848 papers will be published in March 2022, and a continuous upward phase. Research related to genomics is ongoing with the outbreak of COVID-19 and the growing awareness of research needs and potential. The research field of COVID-19 is very diverse and is actively explored by experts and scholars in different disciplines around the world (Figure 1).
Figure 1
Co-occurrence analysis of countries and institutions
The 50 Countries and Institutions with the highest number of occurrences each year are selected for data statistics and visual analysis. Each node represents a country or institution and the connection between nodes represents the cooperation between countries or regions (). Figure 2 shows the cooperative network publications between at least 10 countries or regions. Through this diagram, we can find that the number of papers published by the United States and China is significantly higher than that of other countries, but the centrality is 0, indicating that the United States and China are the global leaders in this field, but have less international cooperation. The top 10 institutions with the most published papers are American universities and related medical institutions in China, suggesting that Chinese Acad Sci and Harvard Med Sch have more in-depth research on COVID-19 genomics. This paper provides evidence to support the importance of genomics in COVID-19 and provides some rationale for it. It is worth noting that, as seen in Table 1, most of the countries with the highest productivity of COve number of articles is closely related to economic development (Figures 2, 3, Table 1).
Figure 2
Table 1
| Ranking | Country | Institution | ||||
|---|---|---|---|---|---|---|
| Country | Frequency | Centrality | Institution | Frequency | Centrality | |
| 1 | USA | 2680 | 0,00 | Chinese Acad Sci | 186 | 0.00 |
| 2 | CHINA | 1620 | 0.00 | Harvard Med Sch | 168 | 0.14 |
| 3 | INDIAN | 775 | 0,04 | Univ Oxford | 138 | 0.15 |
| 4 | ITALY | 730 | 0.00 | Huazhong Univ Sci & Technol | 111 | 0.17 |
| 5 | ENGLAND | 695 | 0.00 | Univ Chinese Acad Sci | 106 | 0.19 |
| 6 | GERMANY | 603 | 0.00 | Univ Cambridge | 97 | 0.23 |
| 7 | CANADA | 388 | 0.03 | Stanford Univ | 94 | 0.00 |
| 8 | FRANCE | 361 | 0.00 | Fudan Univ | 93 | 0.00 |
| 9 | AUSTRALIA | 334 | 0.12 | Univ Washington | 92 | 0.32 |
| 10 | JAPAN | 327 | 0.02 | Imperial Coll London | 88 | 0.16 |
Top 10 countries and institutions with the number of publications on COVID-19 genomics.
Figure 3
Analysis of author co-occurrence and co-citation
Author co-occurrence
The 30 authors with the highest number of occurrences each year were selected for co-occurrence analysis and co-citation analysis. To prevent the problem of homonymy among different authors, the authors with the top 10 published papers were included in this study for manual screening and frequency statistics after download. The results indicated that the authors with higher publication volume had more in-depth research on COVID-19 genomics but with lower centrality, suggesting a low level of cooperation between authors; 19 Research and development in the field of genomics is of great significance.
YANG LIU is the most productive author in terms of the number of publications. They mainly focus on the COVID-19 single-cell transcriptome atlas and the immune characteristics of single-cell sequencing (; ). CHRISTIAN DROSTEN, KWOKYUNG YUEN, KELVIN KAIWANG TO, ANDREW RAMBAUT, and others are also active in this field. From the network map (Figure 4), we can find close annotation among the top 10 authors, which identifies the close collaboration of these professional authors, and most of the research results are from teams specializing in the field of treating COVID-19 genomics.
Figure 4
Author co-citation
Co-citation refers to the phenomenon that two or more authors or their articles are cited by other literature at the same time (). Among the author co-citation, the most cited author was Zhou P, with citation counts of 1694, followed by Anonymous, Zhu N, Hoffmann M, and Huang CL (Figure 5, Table 2). From the cluster review, the authors devoted their minds to Sars-Cov-2, vaccines, and angiotensin-converting enzyme 2 (ACE2) (), as the keywords ranked in the top five.
Figure 5
Table 2
| Ranking | Author’s publication volume | Co-cited author | ||||
|---|---|---|---|---|---|---|
| Author | Frequency | Centrality | Author | Frequency | Centrality | |
| 1 | YANG LIU | 32 | 0.11 | Zhou P | 1694 | 0.40 |
| 2 | CHRISTIAN DROSTEN | 25 | 0.03 | Anonymous | 1528 | 0.17 |
| 3 | KWOKYUNG YUEN | 25 | 0.01 | Zhu N | 1411 | 0.25 |
| 4 | KELVIN KAIWANG TO | 23 | 0.06 | Hoffmann M | 1398 | 0.28 |
| 5 | ANDREW RAMBAUT | 21 | 0.01 | Huang CL | 1222 | 0.08 |
| 6 | MASSIMO CICCOZZI | 20 | 0.03 | Wu F | 1182 | 0.34 |
| 7 | WEI ZHANG | 20 | 0.12 | Corman VM | 1157 | 0.03 |
| 8 | MARTA GIOVANETTI | 20 | 0.04 | Chan JFW | 1092 | 0.02 |
| 9 | EDWARD C HOLMES | 20 | 0.06 | **World Health Organization | 998 | 0.58 |
| 10 | ZHENG ZHANG | 20 | 0.14 | Lu RJ | 965 | 0.00 |
Top 10 authors and co-cited authors in research of COVID-19 genomics.
**means World Health Organization (WHO), WHO is a specialized agency under the United Nations and the largest intergovernmental health organization in the world.
Analysis of journal co-citation and double graph overlay
The 30 most cited journals each year were selected for visual analysis. The results showed that the top 10 most cited journals had higher impact factors. Among them, there are 8 journals with an impact factor greater than 10, namely NEW ENGL J MED, LANCET, JAMA-J AM MED ASSOC, NATURE, SCIENCE, CELL, NAT COMMUN, P NATL ACAD SCI USA, with the highest impact factor of 90.333, indicating that the research in the field of COVID-19 genomics has high research value in the field of medical genomics (Figure 6, Table 3).
Figure 6
Table 3
| Ranking | Journal | Frequency | Centrality | IF Impact factor |
|---|---|---|---|---|
| 1 | NATURE | 5711 | 0.25 | 49.462 |
| 2 | NEW ENGL J MED | 5140 | 0.10 | 90.333 |
| 3 | LANCET | 4663 | 0.02 | 78.528 |
| 4 | SCIENCE | 4527 | 0.00 | 47.728 |
| 5 | CELL | 4090 | 0.18 | 41.582 |
| 6 | P NATL ACAD SCI USA | 3890 | 0.10 | 11.093 |
| 7 | JOURNAL OF VIROLOGY | 3393 | 0.16 | 5.052 |
| 8 | NATURE COMMUNICATION | 3358 | 0.00 | 14.77 |
| 9 | PLOS ONE | 3330 | 0.00 | 3.208 |
| 10 | JAMA-J AM MED ASSOC | 3046 | 0.02 | 55.709 |
Top 10 journals cited in research of atherosclerosis genomics.
IF, Impact factor; NEW ENGL J MED, New England Journal of Medicine; P NATL ACAD SCI USA, Proceedings of the National Academy of Sciences of the United States of America; JAMA-J AM MED ASSOC, Jama-Journal of the American Medical Association.
The 9133 retrieved literature were imported into the CiteSpace software and a double-map overlay of the journals was plotted. The left side is the subject areas of the cited journals, the right side is the subject areas of the cited journals, and the wavy curve is the citations of the journals. The trajectory, that is, the transfer from the subject area of the cited journals to the subject area of the cited journals, is analyzed through the journal double graph overlay to reflect the knowledge flow between the disciplines involved in COVID-19 genomics literature at the journal level. The results show that the cited journals in the orange citation track are concentrated in molecular, biology, immunology, and other disciplines, and the green ones are concentrated in medicine, pharmacy, clinical and other disciplines. The transfer of disciplines such as COVID-19 science and other disciplines indicates that the disciplines concentrated in the covid-19 genomics-related journals have shifted from the fields of molecular biology, biology, immunology, medicine, pharmacy, and clinical to the fields of molecular biology, genetics, etc. The orange path in Figure 7 indicates that the literature published in the journal Molecular/Biology/Genetics is frequently cited in the journal Molecular/Biology/Immunology. Therefore, COVID-19 genomics is closely integrated with basic and clinical disciplines, and the construction of multidisciplinary management needs to be further strengthened in the future (Figure 7).
Figure 7
Analysis of keywords
Analysis of keyword co-occurrence
By analyzing the frequency and centrality of the keywords, the research frontiers can be identified (). Keywords were manually merged and deleted, such as changing covid-19 to covid 19, and changing sar, sars, virus, coronavirus, infection, respiratory syndrome coronavirus to sars-cov-2. Keywords are high-level summaries of literature content and topics, which could diagnose and activate disease scripts and are an integral part of medical culture and language (). T The results show that research hotspots in the field of COVID-19 genomics mainly focus on covid 19, SRAS-COV-2, protein, RNA, ace2, replication, vaccine, expression, spike protein, transmission, and so on. The studies of COVID-19 genomics are developing rapidly and are now of great research value, playing an important role in the development of biomedicine and human health (Figure 8, Table 4).
Figure 8
Table 4
| Ranking | Keywords | ||
|---|---|---|---|
| Keywords | Frequency | Centrality | |
| 1 | covid 19 | 5666 | 0.84 |
| 2 | sars-cov-2 | 3786 | 1.13 |
| 3 | protein | 570 | 0.06 |
| 4 | RNA | 518 | 0.23 |
| 5 | ACE2 | 467 | 0.33 |
| 6 | replication | 406 | 0.29 |
| 7 | vaccine | 397 | 0.29 |
| 8 | expression | 377 | 0.23 |
| 9 | Spike protein | 376 | 0.57 |
| 10 | transmission | 339 | 0.06 |
Top 10 keywords for research in COVID-19 genomics.
Analysis of keywords bursts
The emerging analysis of keywords reveals the directions and trends in this field’s study during a specific period. After doing a burst keywords analysis on the co-occurrence findings of the keywords, a total of 20 emergent words were obtained. Based on the timing of emergence, these words may be roughly split into three categories: (1) 2019-2020 emergent words are quarantine, biological management, poaching, RNA-dependent RNA, polymerase, drug, bat, hand hygiene, angiotensin-converting enzyme-2, China, conservation, social distancing; (2) 2020-2021 emergent words are wuhan, influenza, functional receptor, pneumonia, sars-cov, pathogenesis; (3) 2021-2022 emergent words are molecular docking, messenger RNA, Wuhan, functional receptor, pneumonia, SARS-COV, and pathogenesis were a few of them, listed in order of their emerging intensity from high to low. Most of the co-cited literature has been frequently cited in the past three years, which implies that the outbreak of studies related to COVID-19 genomics is likely to continue in the future (Table 5). As shown in Table 5, there have been three periods of keyword bursts since 2019, and COVID-19 genomics research may continue to grow in the future.
Table 5
| Keywords burst | Year | Strength | Begin | End | 2019-2022 |
|---|---|---|---|---|---|
| quarantine | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| biological management | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| poaching | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| rna-dependent rna polymerase | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| drug | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| bat | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| hand hygiene | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| angiotensin-converting enzyme-2 | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| China | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| wuhan | 2019 | 38.1936 | 2019 | 2020 | ▃▃▂▂ |
| conservation | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| social distancing | 2019 | 0.6924 | 2019 | 2019 | ▃▂▂▂ |
| influenza | 2019 | 17.4734 | 2020 | 2020 | ▂▃▂▂ |
| functional receptor | 2019 | 21.4603 | 2020 | 2020 | ▂▃▂▂ |
| pneumonia | 2019 | 19.8747 | 2020 | 2020 | ▂▃▂▂ |
| sars-cov | 2019 | 19.0675 | 2019 | 2020 | ▂▃▂▂ |
| pathogenesis | 2019 | 19.4661 | 2020 | 2020 | ▂▃▂▂ |
| molecular docking | 2019 | 7.2719 | 2021 | 2022 | ▂▂▃▃ |
| messenger rna | 2019 | 7.3488 | 2021 | 2022 | ▂▂▃▃ |
Bursts in research of atherosclerosis genomics.
Analysis of cited references
According to the number of citations, Zhu N is in first place with 1395 citations. The second place is Hoffmann M with 1193 citations. The third place is Huang CL with 1193 citations. The 4th place is Wu F with 974 citations. The 5th place is Lu RJ with 961 citations. The 6th place is Corman VM, with 917 citations. The 7th place is Zhou P with 808 citations. The 8th place is Walls AC with 678 citations. The 9th place is Wrapp D with 649 citations. The 10th place is Gorbalenya AE with 620 citations (Figure 9, Table 6). Among the 9133 co-cited references retrieved, Table 6 shows the 43 most frequently cited references, of which A New Coronavirus from Patients with Pneumonia in China, 2019 is the most frequently cited (1395). The majority of the co-cited literature was cited frequently since 2019, which implies that studies related to covid-19 genomics may continue to be a hot spot for future research.
Figure 9
Table 6
| Frequency | Centrility | Year | Reference |
|---|---|---|---|
| 1395 | 0.39 | 2020 | Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017 |
| 1193 | 0.05 | 2020 | Hoffmann M, 2020, CELL, V181, P271,DOI 10.1016/j.cell.2020.02.052 |
| 1193 | 0.53 | 2020 | Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5 |
| 974 | 0.16 | 2020 | Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3 |
| 961 | 0.26 | 2020 | Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8 |
| 917 | 0.11 | 2020 | Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045 |
| 808 | 0.00 | 2020 | Zhou P, 2020, NATURE, V588, P0 |
| 678 | 0.1 | 2020 | Walls AC, 2020, CELL, V181, P281 |
| 649 | 0.13 | 2020 | Wrapp D, 2020, SCIENCE, V367, P1260 |
| 620 | 0.00 | 2020 | Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z |
| 591 | 0.05 | 2020 | Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7 |
| 576 | 0.00 | 2020 | Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3 |
| 574 | 0.03 | 2020 | Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7 |
| 529 | 0.03 | 2020 | Guan Wei-Jie, 2020, N ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032 |
| 490 | 0.32 | 2020 | Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9 |
| 482 | 0.05 | 2020 | Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0 |
| 478 | 0.00 | 2020 | Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9 |
| 440 | 0.03 | 2019 | Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9 |
| 440 | 0.11 | 2020 | Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043 |
| 439 | 0.00 | 2020 | Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc200173 |
| 426 | 0.00 | 2020 | Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786 |
| 383 | 0.00 | 2020 | Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577 |
| 335 | 0.08 | 2020 | Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5 |
| 312 | 0.00 | 2020 | Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026 |
| 288 | 0.03 | 2018 | Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407 |
| 264 | 0.00 | 2017 | Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494 |
| 262 | 0.00 | 2020 | Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5 |
| 258 | 0.00 | 2020 | CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011 |
| 254 | 0.00 | 2020 | Wolfel R, 2020, NATURE, V588, P0, DOI 10.1038/s41586-020-2984-3 |
| 252 | 0.00 | 2020 | Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498 |
| 209 , | 0.00 | 2020 | Beigel JH, 2020, NEW ENGL J MEDV383, P1813, DOI 10.1056/NEJMoa2007764 |
| 195 | 0.05 | 2020 | Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585 |
| 179 | 0.00 | 2020 | Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565 |
| 172 | 0.00 | 2020 | Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191 |
| 168 | 0.00 | 2020 | Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762 |
| 156 | 0.00 | 2020 | Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902 |
| 154 | 0.16 | 2020 | Wan YS, 2020, J VIROL, V94, P0, DOI 10.1128/JVI.02015-19 |
| 142 | 0.03 | 2020 | Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X |
| 139 | 0.08 | 2020 | Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282 |
| 136 | 0.00 | 2020 | Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648 |
| 126 | 0.00 | 2020 | Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001 |
| 124 | 0.05 | 2020 | To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1 |
| 123 | 0.00 | 2016 | de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81 |
Centrality and frequency of cited references related to COVID-19 genomics.
Discussion
The literature data collected in the manuscript is from the WOSCC, while CiteSpace software uses information from WOSCC and other database networks (). At present, the commonly used bibliometric software includes VOSViewer, CiteSpace, SCI2, NetDraw and HistCite (). CiteSpace, a bibliometric tool developed by Professor Chen Chaomei, is a popular information visualization method in the field of knowledge mapping (). It is good at exploring cooperation, key points, internal structure, potential trends and dynamics in a certain field (; ). It can be seen that bibliometric software has its unique advantages, and citespace software is relatively complete. Therefore, we use CiteSpace (version 5.6. R3) to analyze and visualize the countries, institutions, authors, journals, co-citations, keywords, etc.
The results of the annual publications in this study show a significant overall upward trend in COVID-19. 2019 is the outbreak period of new coronary pneumonia with a relatively small number of publications; 2020 will see 2431 publications, which is in a period of rapid growth; 5852 papers will be published in 2021, which will continue to grow significantly; and 848 papers will be published before March 2022. The upward trend in the number of articles indicates that the genomics research of COVID-19 has become one of the hottest research fields in the past 3 years. The United States and China are countries with a large number of publications, but the level of cooperation between countries is not high. The research institutions are mainly American and Chinese, and the institution with the most publications is the Chinese Acad Sci.
YANG LIU is the author with the largest number of papers and has conducted in-depth research on COVID-19 involving the inactivated SARS-CoV-2 vaccine BBIBP-CorV (Sinopharm), which is a Chinese vaccine approved for entry by TGA and was found to be tolerable and immunogenic in healthy people through a randomized, double-blind, placebo-controlled Phase 1/2 clinical trial (). Their team established a China COVID-19 Single Cell Consortium (SC4), and large RNA-seq datasets covering different disease severities and stages revealed multiple immune signatures of COVID-19 (). D614G in the USA-WA1/2020 strain enhances replication in human lung epithelial cells and primary airway tissue by enhancing viral particle infectivity and D614G mutation enhances viral load in the upper respiratory tract of COVID-19 patients and may increase transmission. Peter Libby is the most cited author. In addition, Christian Weber is the author of numerous publications and citations (). Zhou P is the most cited author and summarizes the basic biology of SARS-CoV-2, including genetic features, potential zoonotic origin, and its receptor binding and clinical and epidemiological features, diagnosis, and countermeasures of COVID-19 (). They also introduce the protein structure of SARS-CoV-2 and structure-based therapeutic development, including antibodies, antiviral compounds, and vaccines, and point out the limitations and prospects of SARS-CoV-2 research (). In the three years after the outbreak of new coronary heart disease, Chinese people made the greatest contribution to the genomics research of new coronary heart disease, focusing on the research and development of a new coronary heart disease vaccine.
The top 10 most cited journals have high impact factors, with NEW ENGL J MED having the highest impact factor of 90.333, indicating that research in the field of COVID-19 genomics has a high international impact and that the concentration of disciplines of COVID-19 genomics-related journals has shifted from molecular, biology, immunology, medicine, pharmacy, clinical and other disciplines to molecular, biology, genetics and other disciplines.
The results of the analysis of keywords show that the research hotspots in the field of COVID-19. Genomics mainly focus on covid 19, sars-cov-2, protein, RNA, angiotensin-converting enzyme II (ACE2), replication, vaccine, expression, spike protein, transmission and so on. Originally dedicated to determining the sequence of nucleotides on a given stretch of DNA, “genomics” has rapidly expanded to a higher level of function-the study of expression profiles and the roles of genes and proteins (). Remdesivir is currently approved by the FDA for usage in hospitalized COVID-19 patients, although additional information is still required to comprehend the drug’s function in severe COVID-19. Numerous randomized trials of other candidate therapies are underway, including antivirals, antibodies, and immunomodulators (; ; ; ). Genomic studies into COVID-19 are rapidly increasing. With regard to the S gene and receptor binding domain (RBD), the COVID-19 genome and phylogeny are comparable to those of the SARS-CoV-2, indicating the potential for direct human-to-human transmission (). SARS-CoV-2 is currently spreading globally as a highly mutated Omicron variant virus. The genomes, dispersal, and effectiveness of vaccinations against Omicron variations are the main topics of the current study (). However, there is limited information on the status of Omicron variants. ANG proposes that SARS-CoV-2 can be divided into two main lineages (L and S), which can be well defined by two tightly linked single nucleotide polymorphisms (SNPs) at positions 8,782 (orf1ab: T8517C, synonym) and 28, 144 (ORF8: C251T, S84L). Among them, the function of the S84L AA change in ORF8 and the possible roles of these two mutations in the pathogenesis of SARS-CoV-2 ().
Since the genetic information of SARS-CoV-2 was first published, various molecular approaches including reverse transcription polymerase chain reaction (RT-PCR), reverse transcription loop-mediated isothermal amplification (RT-LAMP), real-time RT-LAMP, recombinase polymerase amplification (RPA), genome-wide high-throughput sequencing, and clustered regularly interspersed short palindromic repeats/CRISPR-associated system (CRISPR/Cas)-based methods have been used for genetic testing (). The use of small non-coding RNAs (either endogenous or exogenous) in RNA interference (RNAi) to match target mRNAs (messenger RNAs) in a sequence-specific manner and silence their expression may potentially combat SARS-CoV-2 (). COVID-19 vaccines based on novel mRNA technology are one of the primary preventive measures to protect humans worldwide from COVID-19 (; ).
The keyword with the strongest emergent intensity in this study and lasting into 2019 is wuhan. In addition, studies related to functional receptors, influenza, and pathogenesis are also at the forefront of research on COVID-19. In late December 2019, some patients were admitted to the hospital with an initial diagnosis of pneumonia of unknown etiology, the first appearance of which may be considered epidemiologically related to the seafood and wet animal wholesale market in Wuhan, Hubei Province, China (; ; ). Human angiotensin-converting enzyme II (hACE2) has been identified as a functional receptor for SARS-CoV-2. Sun et al. used CRISPR/Cas9 knock-in technology to generate a mouse model expressing hACE2 and discovered that hACE2 mice maintained high viral loads in the lungs, trachea, and brain following intranasal infection. They also found interstitial pneumonia and elevated cytokines were found in aged hACE2 mice that were infected with SARS-CoV-2 (). While the genomic pathogenesis and process of covid-19 are through spike binding to ACE2, allowing SARS-CoV-2 to enter and infect cells, the spike protein must be triggered by a protease called TMPRSS2 (). After the virus enters the host cell and uncoats, the genome is transcribed and then translated, a process involved in the coordination of continuous and discontinuous RNA synthesis mediated by viral replication (; ).
In addition, we should also pay close attention to the still popular research topics of molecular docking and mRNA that appeared in 2021. Molecular docking is structural molecular biology and computer-aided drug design that can be used to virtually screen large compound libraries, rank results, and propose structural hypotheses about how ligands inhibit targets (). Molecular docking technology is widely used in COVID-19, such as the use of Huashi Baidu formula (HSBDF) in China to treat patients with severe COVID-19, where baicalein and quercetin were found to be compounds with high affinity for ACE2 through network pharmacology and molecular docking (). In clinical observations and randomized controlled trials, Lianhua Qingwen Capsules were protective against SARS-CoV-2 infection and COVID-19 (). Molecular docking of Lianhua Qingwen capsules shows the interaction mode between effective molecules and targeted proteins, revealing the active pockets of Serine/threonine-protein kinase AKT (Akt1), namely β-carotene, kaempferol, luteolin, naringenin, quercetin, rhein, forsythoside A, and wogonin, which reduce tissue damage and contribute to the elimination of COVID-19 infection (; ; ). In the past few years, messenger RNA (mRNA) has emerged as a promising class of drugs for the treatment of a variety of diseases (). T The BNT162b2 messenger RNA vaccine has demonstrated efficacy against SARS-CoV-2 (; ).
Most of the current research on COVID-19 has focused on detection techniques, vaccine prevention, and treatment strategies. We found that a few months after the outbreak of COVID-19, Maryam Okhovati et al. found through visual analysis of bibliometrics that the research cluster in China was “quantitative testing” and the United States was “biological assessment” (). There are also the bibliometric statistics of COVID-19 from the perspectives of the eyes () and ENT department (). We performed statistical and visual analysis of COVID-19 genomics by searching the 2019-2022, countries, institutions, authors, journals, coreferences and keywords. The research hotspots of COVID-19 revolve around quarantine, biological management, angiotensin-converting enzyme-2, RNA-dependent RNA, polymerase, etc. Research fronts and trends focus on molecular docking, messenger RNA, functional receptor, etc. In addition, the existing review articles do not reveal the key issues of the current research hotspots in COVID-19 genomics.
This study has several unique advantages. First of all, we provide the first systematic analysis of genomics studies of COVID-19 through bibliometrics, providing a comprehensive guide for scholars who pay attention to related research. Secondly, the bibliometric analysis provides a more comprehensive insight into hotspots and frontiers than traditional reviews. Last but not least, previous studies have focused on detection techniques used to diagnose COVID-19 infections, emerging variants, and vaccine development and prevention. In the present study, we focused on the role of genomics in COVID-19 and gave a new interpretation of COVID-19 at the molecular level.
Of course, this study also has some shortcomings. First of all, the data for this study were only from the WoSCC database. Other databases such as Scopus or Google were ignored, and some relevant research may be omitted. Secondly, we only used the CiteSpace measurement tool in our survey. VOSviewer (), NetDraw (), HistSite () were not involved in the survey. We believed that the combination of one or two databases will make the experimental data more accurate and comprehensive in future studies.
Conclusion
In summary, this study used CiteSpace software to visualize countries, institutions, authors, journals, literature, keywords, etc. in the WOS from 2019 to 2022 on COVID-19 genomics. Based on the above bibliometric analysis, the main conclusions of this study can be summarized as follows: (1) COVID-19 broke out in 2019, and there was little research on genomics. The number of research in this field has increased rapidly since 2020; (2) The countries, institutions, and authors of COVID-19 genomics are mainly concentrated in countries such as the United States, China, and India; (3)Its research hotspots are focused on the sars-cov-2 virus, functional receptor, pathogenesis, molecular docking, mRNA, which are the prospects for further research in the field of COVID-19 genomics. This research provides a reference for new drug development and vaccine update.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.
Author contributions
Conceptualization: Z-YP, XZ. Data curation: X-MP, J-JS. Methodology: X-MP, B-CZ. Visualization: X-MP. All authors contributed to the article and approved the submitted version.
Funding
Shandong Medical and Health Science and Technology Development Plan: LncRNA MEG3 Regulates NF- κB Study on the mechanism of B signal pathway inhibiting A549 cell growth (No.: 202003020847).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Footnotes
AI, Artificial intelligence; Akt1, Serine/threonine-protein kinase AKT; BBIBP-CorV (Sinopharm, Chinese vaccines approved for entry by TGA; Chinese Acad Sci, Chinese Academy of Sciences; COVID-19, Corona Virus Disease 2019; CRISPR/Cas CRISPR, associate system; hACE2, Human angiotensin-converting enzyme II; Harvard Med Sch, Harvard Medical School; HSBDF, Huashi Baidu formula; messenger RNAs, mRNAs; RBD, receptor binding domain; RNAi, RNA interference; RPA, Recombinase polymerase amplification; RT-LAMP, reverse transcription loop-mediated isothermal amplification; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SNPs, single nucleotide polymorphisms; SC4, Single Cell Consortium for COVID-19 in China; VOC, variants of concern; WOSCC, Web of Science Core Collection Database.
References
1
AbubakerB. S.IbrahimN. K.AbubakerB. H.HashemA. R. (2022). Covid-19 and artificial intelligence: Genome sequencing, drug development and vaccine discovery. J. Infect. Public Health15 (2), 289–296. doi: 10.1016/j.jiph.2022.01.011
2
ArafY.AkterF.TangY. D.FatemiR.ParvezM. S. A.ZhengC.et al. (2022). Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J. Med. Virol.94 (5), 1825–1832. doi: 10.1002/jmv.27588
3
BaiC.ZhongQ.GaoG. F. (2022). Overview of SARS-CoV-2 genome-encoded proteins. Sci. China Life Sci.65 (2), 280–294. doi: 10.1007/s11427-021-1964-4
4
BergwerkM.GonenT.LustigY.AmitS.LipsitchM.CohenC.et al. (2021). Covid-19 breakthrough infections in vaccinated health care workers. N Engl. J. Med.385 (16), 1474–1484. doi: 10.1056/NEJMoa2109072
5
BerlinD. A.GulickR. M.MartinezF. J. (2020). Severe covid-19. N Engl. J. Med.383 (25), 2451–2460. doi: 10.1056/NEJMcp2009575
6
BogochI. I.WattsA.Thomas-BachliA.HuberC.KraemerM. U. G.KhanK. (2020). Pneumonia of unknown aetiology in wuhan, China: potential for international spread via commercial air travel. J. Travel Med.27, (2). doi: 10.1093/jtm/taaa008
7
ChanM. W.EppichW. J. (2020). The keyword effect: A grounded theory study exploring the role of keywords in clinical communication. AEM Educ. Train4 (4), 403–410. doi: 10.1002/aet2.10424
8
ChenC.HuZ.LiuS.TsengH. (2012). Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin. Biol. Ther.12 (5), 593–608. doi: 10.1517/14712598.2012.674507
9
ChenY.LinM.ZhuangD. (2022). Wastewater treatment and emerging contaminants: Bibliometric analysis. Chemosphere297, 133932. doi: 10.1016/j.chemosphere.2022.133932
10
ChenX.WuY.ChenC.GuY.ZhuC.WangS.et al. (2021). Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm. Sin. B11 (1), 222–236. doi: 10.1016/j.apsb.2020.10.002
11
ChenN.ZhouM.DongX.QuJ.GongF.HanY.et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, China: a descriptive study. Lancet395 (10223), 507–513. doi: 10.1016/S0140-6736(20)30211-7
12
ChoyK. T.WongA. Y.KaewpreedeeP.SiaS. F.ChenD.HuiK. P. Y.et al. (2020). Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res.178, 104786. doi: 10.1016/j.antiviral.2020.104786
13
DelG. L.CattaneoC. (2012). Introduction to genomics. Methods Mol. Biol.823, 79–88. doi: 10.1007/978-1-60327-216-2_6
14
DouaudG.LeeS.Alfaro-AlmagroF.ArthoferC.WangC.McCarthyP.et al. (2022). SARS-CoV-2 is associated with changes in brain structure in UK biobank. Nature604(7907), 697–707. doi: 10.1038/s41586-022-04569-5
15
GaoY.ShiS.MaW.ChenJ.CaiY.GeL.et al. (2019). Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. Int. Immunopharmacol72, 374–384. doi: 10.1016/j.intimp.2019.03.045
16
GuoY. R.CaoQ. D.HongZ. S.TanY. Y.ChenS. D.JinH. J.et al. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med. Res.7 (1), 11. doi: 10.1186/s40779-020-00240-0
17
HarveyW. T.CarabelliA. M.JacksonB.GuptaR. K.ThomsonE. C.HarrisonE. M.et al. (2021). SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol.19 (7), 409–424. doi: 10.1038/s41579-021-00573-0
18
HassanW.ZafarM.DuarteA. E.KamdemJ. P.Teixeira da RochaJ. B. (2021). Pharmacological research: A bibliometric analysis from 1989 to 2019. Pharmacol. Res.169, 105645. doi: 10.1016/j.phrs.2021.105645
19
HoffmannM.Kleine-WeberH.SchroederS.KrügerN.HerrlerT.ErichsenS.et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell181 (2), 271–280.e8. doi: 10.1016/j.cell.2020.02.052
20
HuB.GuoH.ZhouP.ShiZ. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol.19 (3), 141–154. doi: 10.1038/s41579-020-00459-7
21
JainS.VenkataramanA.WechslerM. E.PeppasN. A. (2021). Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv. Drug Delivery Rev.179, 114000. doi: 10.1016/j.addr.2021.114000
22
JiangR. D.LiuM. Q.ChenY.ShanC.ZhouY. W.ShenX. R.et al. (2020). Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell182 (1), 50–58.e8. doi: 10.1016/j.cell.2020.05.027
23
KimV. N.HanJ.SiomiM. C. (2009). Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol.10 (2), 126–139. doi: 10.1038/nrm2632
24
KnyazevS.ChhuganiK.SarwalV.AyyalaR.SinghH.KarthikeyanS.et al. (2022). Unlocking capacities of genomics for the COVID-19 response and future pandemics. Nat. Methods19 (4), 374–380. doi: 10.1038/s41592-022-01444-z
25
LaineC.CottonD.MoyerD. V. (2021a). COVID-19 vaccine distribution and allocation: What physicians need to know. Ann. Intern. Med.174 (3), 413–414. doi: 10.7326/M21-0331
26
LaineC.CottonD.MoyerD. V. (2021b). COVID-19 vaccine: Promoting vaccine acceptance. Ann. Intern. Med.174 (2), 252–253. doi: 10.7326/M20-8008
27
LinM.ChenY.ChenR. (2021). Bibliometric analysis on Pythagorean fuzzy sets during 2013–2020. Int. J. Intelligent Computing Cybernetics14 (2), 104–121. doi: 10.1108/IJICC-06-2020-0067
28
LiuJ.CaoR.XuM.WangX.ZhangH.HuH.et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery6, 16. doi: 10.1038/s41421-020-0156-0
29
LiX.YangY.LiuL.YangX.ZhaoX.LiY.et al. (2020). Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019. Pharmacol. Res.160, 105036. doi: 10.1016/j.phrs.2020.105036
30
LiB.ZhangX.DongY.et al. (2019). Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip Rev. Nanomed Nanobiotechnol.11 (2), e1530. doi: 10.1002/wnan.1530
31
LuoY.LinM. (2021). Flash translation layer:a review and bibliometric analysis. Int. J. Intelligent Computing Cybernetics (English)003), 014. doi: 10.1108/IJICC-02-2021-0034
32
LuH.StrattonC. W.TangY. W.et al. (2020). Outbreak of pneumonia of unknown etiology in wuhan, China: The mystery and the miracle. J. Med. Virol.92 (4), 401–402. doi: 10.1002/jmv.25678
33
MorrisG. M.Lim-WilbyM. (2008). Molecular docking. Methods Mol. Biol.443, 365–382. doi: 10.1007/978-1-59745-177-2_19
34
MousavizadehL.GhasemiS. (2021). Genotype and phenotype of COVID-19: Their roles in pathogenesis. J. Microbiol. Immunol. Infect.54 (2), 159–163. doi: 10.1016/j.jmii.2020.03.022
35
MugheesM.ChughH.NaqviS. H.WajidS. (2021). COVID-19 threat to the world: Current and possible Diagnostic/Treatment strategies. Crit. Rev. BioMed. Eng.49 (1), 21–33. doi: 10.1615/CritRevBiomedEng.2021036595
36
NieN. F.HeY. (2020). [Potential therapeutic drugs for novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi43 (11), 970–974. doi: 10.3760/cma.j.cn112147-20200226-00191
37
OkhovatiM.ArshadiH. (2021). COVID-19 research progress: Bibliometrics and visualization analysis. Med. J. Islam Repub Iran35, 20. doi: 10.47176/mjiri.35.20
38
PanH.XiZ.YuX.SunX.WeiX.WangK. (2021). Knowledge mapping analysis of international research on acupuncture for low back pain using bibliometrics. J. Pain Res.14, 3733–3746. doi: 10.2147/JPR.S340992
39
PeiW.PengR.GuY.ZhouX.RuanJ. (2019). Research trends of acupuncture therapy on insomnia in two decades (from 1999 to 2018):a bibliometric analysis. BMC Complement Altern. Med.19 (1), 225. doi: 10.1186/s12906-019-2606-5
40
PlanteJ. A.LiuY.LiuJ.XiaH.JohnsonB. A.LokugamageK. G.et al. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature592 (7852), 116–121. doi: 10.1038/s41586-020-2895-3
41
RahimiA.MirzazadehA.TavakolpourS. (2021). Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics113 (1 Pt 2), 1221–1232. doi: 10.1016/j.ygeno.2020.09.059
42
RaminS.PakravanM.et al. (2016). Scientometric analysis and mapping of 20 years of glaucoma research. Int. J. Ophthalmol.9 (9), 1329–1335. doi: 10.18240/ijo.2016.09.17
43
RenX.WenW.et al. (2021). COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell184 (7), 1895–1913.e19. doi: 10.1016/j.cell.2021.01.053
44
RothanH. A.ByrareddyS. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun109, 102433. doi: 10.1016/j.jaut.2020.102433
45
SafiabadiT. S.LeBlancJ. J.SadiqZ.OyewunmiO. D.CamargoC.NikpourB.et al. (2021). Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin. Microbiol. Rev.34, (3). doi: 10.1128/CMR.00228-20
46
Sánchez-TenaM.Á.Martinez-PerezC.Villa-CollarC.Alvarez-PeregrinaC. (2021). Impact of COVID-19 at the ocular level: A citation network study. J. Clin. Med.10, (7). doi: 10.3390/jcm10071340
47
SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA. (2006). New insights into the antiviral effects of chloroquine. Lancet Infect. Dis.6 (2), 67–69. doi: 10.1016/S1473-3099(06)70361-9
48
SeyedH. E.RiahiK. N.NikzadH.AzadbakhtJ.Hassani BafraniH.Haddad KashaniH. (2020). The novel coronavirus disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology551, 1–9. doi: 10.1016/j.virol.2020.08.011
49
ShenJ.ShenH.KeL.ChenJ.DangX.LiuB.et al. (2022). Knowledge mapping of immunotherapy for hepatocellular carcinoma: A bibliometric study. Front. Immunol.13, 815575. doi: 10.3389/fimmu.2022.815575
50
ShiY.LuoJ.WangX.ZhangY.ZhuH.SuD.et al. (2022). Emerging trends on the correlation between neurotransmitters and tumor progression in the last 20 years: A bibliometric analysis via CiteSpace. Front. Oncol.12, 800499. doi: 10.3389/fonc.2022.800499
51
SunS. H.ChenQ.GuH. J.YangG.WangY. X.HuangX. Y.et al. (2020). A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe28 (1), 124–133.e4. doi: 10.1016/j.chom.2020.05.020
52
TangX.WuC.LiX.SongY.YaoX.WuX.et al. (2020). On the origin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev.7 (6), 1012–1023. doi: 10.1093/nsr/nwaa036
53
TaoQ.DuJ.LiX.ZengJ.TanB.XuJ. (2020). Network pharmacology and molecular docking analysis on molecular targets and mechanisms of huashi baidu formula in the treatment of COVID-19. Drug Dev. Ind. Pharm.46 (8), 1345–1353. doi: 10.1080/03639045.2020.1788070
54
UsmanM.HoY. S. (2021). COVID-19 and the emerging research trends in environmental studies: a bibliometric evaluation. Environ. Sci. pollut. Res. Int.28 (14), 16913–16924. doi: 10.1007/s11356-021-13098-z
55
WangM.CaoR.ZhangL.YangX.LiuJ.XuM.et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.30 (3), 269–271. doi: 10.1038/s41422-020-0282-0
56
WangJ.LiangS.YuM.GongZ. (2022). COVID-19 from the perspective of otorhinolaryngology: An analysis of bibliometrics. Front. Public Health10, 1002686. doi: 10.3389/fpubh.2022.1002686
57
WangM. Y.ZhaoR.GaoL. J.GaoX. F.WangD. P.CaoJ. M. (2020). SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front. Cell Infect. Microbiol.10, 587269. doi: 10.3389/fcimb.2020.587269
58
XiaoM.TianJ.ZhouY.XuX.MinX.LvY.et al. (2020). Efficacy of huoxiang zhengqi dropping pills and lianhua qingwen granules in treatment of COVID-19: A randomized controlled trial. Pharmacol. Res.161, 105126. doi: 10.1016/j.phrs.2020.105126
59
XiaQ. D.XunY.LuJ. L.LuY. C.YangY. Y.ZhouP.et al. (2020). Network pharmacology and molecular docking analyses on lianhua qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell Prolif53 (12), e12949. doi: 10.1111/cpr.12949
60
XiaS.ZhangY.WangY.WangH.YangY.GaoG. F.et al. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis.21 (1), 39–51. doi: 10.1016/S1473-3099(20)30831-8
61
YanY.ZouZ.SunY.LiX.XuK. F.WeiY.et al. (2013). Anti-malaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model. Cell Res.23 (2), 300–302. doi: 10.1038/cr.2012.165
62
YuD. J.XuZ. S.WangW. D. (2018). Bibliometric analysis of fuzzy theory research in China: A 30-year perspective. Knowledge-Based Syst.141, 188–199. doi: 10.1016/j.knosys.2017.11.018
63
YuD. J.XuZ. S.HamidoF. (2019). Bibliometric analysis on the evolution of applied intelligence. Appl. Intell.49 (2), 449–462. doi: 10.1007/s10489-018-1278-z
64
YuD. J.XuZ. S.PedryczW. (2020). Bibliometric analysis of rough sets research. Appl. Soft Computing94, 135. doi: 10.1016/j.asoc.2020.106467
65
ZhangJ.LinM. (2022). A comprehensive bibliometric analysis of Apache hadoop from 2008 to 2020. Int. J. Intelligent Computing Cybernetics ahead-of-print. 6(7), 1012–1023. doi: 10.1108/IJICC-01-2022-0004
66
ZhangL.LingJ.LiM. (2022). Artificial intelligence in renewable energy: A comprehensive bibliometric analysis. Energy Rep.8, 14072–14088. doi: 10.1016/j.egyr.2022.10.347
67
ZhangJ.SongL.XuL.FanY.WangT.TianW.et al. (2021). Knowledge domain and emerging trends in ferroptosis research: A bibliometric and knowledge-map analysis. Front. Oncol.11, 686726. doi: 10.3389/fonc.2021.686726
68
ZhongM.LinM. (2022). Bibliometric analysis for economy in COVID-19 pandemic. Heliyon8 (9), e10757. doi: 10.1016/j.heliyon.2022.e10757
69
ZhuL.YangP.ZhaoY.ZhuangZ.WangZ.SongR.et al. (2020). Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity53 (3), 685–696.e3. doi: 10.1016/j.immuni.2020.07.009
70
ZhuN.ZhangD.WangW.LiX.YangB.SongJ.et al. (2020). A novel coronavirus from patients with pneumonia in China 2019. N Engl. J. Med.382 (8), 727–733. doi: 10.1056/NEJMoa2001017
Summary
Keywords
bibliometric analysis, visual analysis, research hotspots, CiteSpace software, genomics, COVID-19
Citation
Pang X, Peng Z, Zheng X, Shi J and Zhou B (2022) Analysis of research hotspots in COVID-19 genomics based on citespace software: Bibliometric analysis. Front. Cell. Infect. Microbiol. 12:1060031. doi: 10.3389/fcimb.2022.1060031
Received
07 October 2022
Accepted
23 November 2022
Published
12 December 2022
Volume
12 - 2022
Edited by
Mingwei Lin, Fujian Normal University, China
Reviewed by
Dejian Yu, Nanjing Audit University, China; Jie Ling, Fujian Normal University, China
Updates
Copyright
© 2022 Pang, Peng, Zheng, Shi and Zhou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhao yun Peng, pzy1506668204@163.com; Xin Zheng, zx15606450752@163.com
This article was submitted to Virus and Host, a section of the journal Frontiers in Cellular and Infection Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.